Study population
CCS angina, dyspnea, impaired vision, chest pain, anemia, CAD, valvular disease, angina pectoris
PULMONARY DISEASE, ANEMIA, CONCOMITANT DISEASE, CAD
This study was designed as a prospective randomized and controlled trial to investigate the effect of visual demonstration of successful PCI on quality of life and angina pectoris in patients with symptomatic stable CAD. The details of the study design have been published previously [Between April 2019 and September 2020, consecutive symptomatic patients undergoing PCI at five academic centers and large community hospitals in Germany were screened for eligibility. Main inclusion criteria were as follows: age ≥ 18 years, symptomatic CAD, CCS angina score ≥ 2, angina pectoris frequency ≥ 2/week, and successful implantation of ≥ 1 coronary artery stent, i.e., complete revascularization of the culprit lesion. Main exclusion criteria were as follows: concomitant disease that could cause dyspnea or chest pain (i.e., left ventricular ejection fraction < 35%; anemia; severe pulmonary disease; severe valvular disease); conditions that prevented sufficient understanding of the visual demonstration and explanation of the angiographic results (language barrier; impaired vision or hearing; dementia).The study complied with the Declaration of Helsinki. Each study site obtained approval by the local ethics committee (Reference number 19-1261-101) and all patients provided written informed consent for participation. The German Clinical Trials Register registration number is DRKS00017524.